UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES
EXCHANGE ACT OF 1934
Dated
April
23, 2015
Commission
File Number 001-36421
AURINIA PHARMACEUTICALS INC.
(Exact
name of Registrant as specified in its charter)
N/A
(Translation of Registrant’s Name)
#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250)
708-4272
(Address and telephone number of registrant’s
principle executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ⃞ Form 40-F ⊠
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): ⃞
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ⃞
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ⃞ No ⊠
If "Yes" is
marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Dated: |
April 23, 2015 |
|||
|
Aurinia Pharmaceuticals Inc. |
||||
|
|
||||
|
|
|
By: |
/s/ Michael R. Martin |
|
| Name: |
Michael R. Martin |
|||
|
|
|
Title: |
Chief Operating Officer |
|
EXHIBIT INDEX
|
Exhibit |
Description of Exhibit |
|
| 99.1 |
News Release – Aurinia Pharmaceuticals to Host Lupus Nephritis Opinion Leader Meeting and Webcast on May 5 in New York |
3
Exhibit 99.1
Aurinia
Pharmaceuticals to Host Lupus Nephritis Opinion Leader Meeting
and
Webcast on May 5 in New York
VICTORIA, British Columbia--(BUSINESS WIRE)--April 23, 2015--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP) today announced it will host a Lupus Key Opinion Leader breakfast on Tuesday, May 5 from 8:00 to 9:30 EDT in New York.
The topic of the meeting will be: Lupus Nephritis: Are early markers predictive of long-term outcomes? and will feature David Wofsy, M.D., Professor of Medicine and Microbiology/Immunology at the University of California San Francisco. He also serves as Associate Dean for Admissions at the UCSF School of Medicine. Dr. Wofsy’s research career has been devoted to the development of novel therapies for systemic lupus erythematosus (SLE), first through studies in murine models and more recently through the conduct of clinical trials. In addition to his studies of novel approaches to the treatment of SLE, Dr. Wofsy has been a leader in identifying early clinical predictors of long-term outcome in patients with lupus nephritis. Dr. Wofsy received his M.D. from the University of California San Diego and subsequently underwent internal medicine residency and rheumatology fellowship training at UCSF. He has been Chief of the Division of Rheumatology at the San Francisco VA Medical Center and Director of the Dept. of Medicine Clinical Trials Center at UCSF. Dr. Wofsy also served as President of the American College of Rheumatology (2003-04).
Dr. Neil Solomons, Aurinia’s Chief Medical Officer will also provide a brief overview and details of the company’s ongoing lupus nephritis studies.
A live webcast of the event will be available at: http://lifesci.rampard.com/20150505 and on the Investors section of the Company’s website at http://www.auriniapharma.com/dnn/ForInvestors.aspx.
The event is intended for qualified institutional investors and sell-side analysts. To attend please contact Mac MacDonald: 212-915-2567 or mac@lifesciadvisors.com
About Aurinia
Aurinia is a clinical stage
pharmaceutical company focused on the global nephrology market. It is
currently enrolling patients in its Phase 2b clinical trial to evaluate
the efficacy of its drug, voclosporin, as a treatment for LN. LN is an
inflammation of the kidneys, that if inadequately treated can lead to
end-stage renal disease, making LN a serious and potentially
life-threatening condition. Voclosporin is a novel and potentially best
in class calcineurin inhibitor (CNI) with extensive clinical data in
more than 2,600 patients in other indications. Voclosporin is made by a
modification of a single amino acid of the cyclosporine molecule (a CNI
approved for use in transplant patients since 1983). This modification
results in a more predictable pharmacokinetic and pharmacodynamic
relationship, an increase in potency vs. cyclosporine, an altered
metabolic profile, and potential for flat dosing. Aurinia also has
development and commercialization partners in Canada, Israel, South
Africa and Greater China.We seek Safe Harbor.
CONTACT:
Aurinia Pharmaceuticals Inc.
Stephen Zaruby, 250-708-4293
President
& Chief Executive Officer
szaruby@auriniapharma.com
or
Mr.
Michael Martin, 250-708-4272
Chief Operating Officer
mmartin@auriniapharma.com